About Samsung Bioepis
Samsung Bioepis is a Healthcare company based in Incheon (South Korea) founded in 2012, and was acquired by Samsung BioLogics in January 2022. Its website samsungbioepis.com draws about 16 thousand monthly visits. Its focus areas include Life Sciences, Dermatology, Drugs and Psoriasis. Its legal entity is Samsung Bioepis Co., Ltd.
Company details
Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohns disease. Ontruzant is Samsung Bioepis first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.
- Headquarters Incheon, South Korea
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website samsungbioepis.com
- Social LinkedIn X
- Acquired by Samsung BioLogics (Jan 2022)
- Legal Name Samsung Bioepis Co., Ltd
- Annual Revenue$660.03 M (USD)2as on Dec 31, 2020
- Net Profit$117.14 M (USD)-48as on Dec 31, 2020
- Investors
- Acquired bySamsung BioLogics
(Jan 2022)
Investors in Samsung Bioepis
Samsung Bioepis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Samsung BioLogics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Contract development and manufacturing for biologics are provided. | 2011 | samsungbiologics.com | Incheon, South Korea |
Investor details for Samsung Bioepis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Samsung Bioepis
2 dated milestones of Samsung Bioepis across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Samsung Bioepis is founded.
- Exit Acquired by Samsung BioLogics.
Web traffic of Samsung Bioepis
The website of Samsung Bioepis (samsungbioepis.com) receives about 16.1K visits a month and ranks #1,543,552 among all websites worldwide, #2,046 in Biotechnology and Pharmaceuticals.
- Monthly visits16.1K
▲ 34.9% vs previous month
- Unique visitors5.5K
per month
- Global rank#1,543,552
among all websites
- Category rank#2,046
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit3.5
- Average visit1 min 11 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Samsung Bioepis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| samsungbiologics.com | 100% | 52K | #483,833 | View details | |
medicinesforeurope.com | medicinesforeurope.com | 95% | #2,288,842 | – | |
| centerforbiosimilars.com | 93% | #1,696,301 | View details | ||
| sandoz.com | 89% | 195.3K | #232,061 | View details | |
rootsanalysis.com | rootsanalysis.com | 89% | #710,325 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Samsung Bioepis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Samsung Bioepis
Complete news archive for Samsung Bioepis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Samsung Bioepis
Samsung Bioepis was founded in 2012.
Samsung Bioepis is headquartered in Incheon, South Korea.
Annual revenue of Samsung Bioepis is $660.03M as on Dec 31, 2020.
Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohns disease. Ontruzant is Samsung Bioepis first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.
Samsung Bioepis has 1 investor. Key investors include Samsung BioLogics.
Samsung Bioepis operates through Samsung Bioepis Co., Ltd.
Yes. Samsung Bioepis was acquired by Samsung BioLogics in January 2022.